MabVax Therapeutics Holdings, Inc. (MBVX) Posts Earnings Results, Misses Estimates By $0.78 EPS
MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX) released its quarterly earnings data on Monday. The company reported ($1.47) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.69) by $0.78, Bloomberg Earnings reports.
MabVax Therapeutics Holdings (NASDAQ MBVX) traded down 4.6229% during trading on Wednesday, hitting $0.4869. 72,618 shares of the stock were exchanged. The stock has a 50 day moving average of $0.95 and a 200-day moving average of $1.90. The stock’s market cap is $4.24 million. MabVax Therapeutics Holdings has a 52 week low of $0.49 and a 52 week high of $6.05.
MabVax Therapeutics Holdings Company Profile
MabVax Therapeutics Holdings, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes proprietary human monoclonal antibody products and vaccines for the treatment of various cancers. The company has a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers.
Receive News & Ratings for MabVax Therapeutics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MabVax Therapeutics Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.